Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs

Title
Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs
Authors
이현범Jose I. JuncosaRichard B. Silverman
Keywords
ornithine aminotransferase (OAT); gamma-aminobutyric acid aminotransferase(GABA-AT); hepatocellular carcinoma (HCC); irreversible enzyme inhibition
Issue Date
2015-03
Publisher
Medicinal research reviews
Citation
VOL 35, NO 2-305
Abstract
Ornithine aminotransferase (OAT) and γ -aminobutyric acid aminotransferase (GABA-AT) are classified under the same evolutionary subgroup and share a large portion of structural, functional, and mechanistic features. Therefore, it is not surprising that many molecules that bind to GABA-AT also bind well to OAT. Unlike GABA-AT, OAT had not been viewed as a potential therapeutic target until recently; consequently, the number of therapeutically viable molecules that target OAT is very limited. In this review the two enzymes are compared with respect to their active-site structures, catalytic and inactivation mechanisms, and selective inhibitors. Insight is offered that could aid in the design and development of new selective inhibitors of OAT for the treatment of cancer.
URI
http://pubs.kist.re.kr/handle/123456789/64622
ISSN
0198-6325
Appears in Collections:
KIST Publication > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE